<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00154180</url>
  </required_header>
  <id_info>
    <org_study_id>KLRI-04-1</org_study_id>
    <secondary_id>WIRB Protocol #20040792</secondary_id>
    <nct_id>NCT00154180</nct_id>
    <nct_alias>NCT00623311</nct_alias>
  </id_info>
  <brief_title>Kronos Early Estrogen Prevention Study (KEEPS)</brief_title>
  <official_title>Effects of Estrogen Replacement on Atherosclerosis Progression in Recently Menopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kronos Longevity Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Albert Einstein College of Medicine, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kronos Longevity Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will examine the effects of estrogen and progesterone on the development of
      atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the
      menopausal transition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The KEEPS is designed to explore the hypothesis that early initiation of hormone therapy, in
      women who are at the inception of their menopause, will decrease the rate of accumulation of
      atherosclerotic plaque, indicating a likely delay in the onset of clinical cardiovascular
      disease. The study is designed as a multicenter, 4 year randomized clinical trial. It will
      evaluate the effectiveness of of 0.45 mg/day of oral conjugated equine estrogens or 50
      mcg/day of transdermal estradiol via skin patch changed weekly (each in combination with
      cyclic oral, micronized progesterone, 200 mg daily for 12 days per month), versus placebo in
      preventing progression of carotid intimal medial thickness by sonogram and the accrual of
      coronary calcium in women aged 42-58 who are within 36 months of their final menstrual period
      at initiation of treatment. A number of secondary endpoints including biochemical and genetic
      risk factors for cardiovascular and thrombotic disease, and effects on cognition will also be
      studied. The study will enroll a total of 720 women in 2005-6, with an anticipated completion
      of the trial in 2010.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2005</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of change of carotid intimal medial thickness by ultrasound</measure>
    <time_frame>Measured at screening, 12, 24, 36, and 48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in coronary calcium score by X-ray tomography</measure>
    <time_frame>Meassured at screening and at 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma lipid profiles</measure>
    <time_frame>Samples taken at screening , 12, 36, and 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood clotting factors</measure>
    <time_frame>Samples taken at screening, 12, 36 and 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum inflammatory factors</measure>
    <time_frame>Samples taken at screening, 12, 36 and 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormone levels</measure>
    <time_frame>Samples taken at screening, 12, 36 and 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive and Affective scores on standard psychometric tests</measure>
    <time_frame>Testing is conducted at Baseline, 18, 36 and 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Measured at Baseline, 18, 36 and 48 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">728</enrollment>
  <condition>Menopause</condition>
  <condition>Arteriosclerosis</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CEE 0.45 mg w/ Prometrium 200 mg patch 0.05 mg w/ Prometrium 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo patch, placebo CEE, placebo Prometrium</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conjugated equine estrogens 0.45 mg/day</intervention_name>
    <description>Pill, 1 pill taken daily each month for the study duration</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Premarin or placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal estradiol, 50 mcg/day</intervention_name>
    <description>Patch; 1 patch is applied to the skin weekly. Patch site is rotated on a weekly basis.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Climara 50 mcg/day or placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micronized progesterone, 200 mg/day x 12 d/month</intervention_name>
    <description>capsule, 1 capsule taken daily for the first 12 days of each month for the study duration</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Prometrium or placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CEE , progesterone, estradiol patch or placebo for each</intervention_name>
    <description>CEE 0.45mg 1 PO QD Progesterone 200 mg 1 PO HS first 12 days of the month estradiol patch use 1 per week</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Premarin</other_name>
    <other_name>Prometrium</other_name>
    <other_name>Climara Patch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CEE, progesterone, transdermal patch or the placebo</intervention_name>
    <description>CEE 0.45 mg 1 PO QD or placebo equivalent Prometrium 200 mg 1 PO qHS for first 12 dasy of each month or placebo equivalent transdermal patch 0.05 mg use 1 patch per week or placebo equivalent</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Premarin</other_name>
    <other_name>Prometrium</other_name>
    <other_name>Climara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  menses absent for at least 6 months and no more than 36 months

          -  good general health

          -  plasma FSH level greater than or equal to 35 mIU/ml

          -  estradiol levels &lt; 40 pg/ml

          -  normal mammogram within 1 year of randomization

        Exclusion Criteria:

          -  use of hormone replacement or supplement within 3 months of randomization

          -  endometrial thickness &gt;5 mm by vaginal ultrasound

          -  in utero exposure to diethylstilbestrol (DES)

          -  current smoking &gt; 10 cigarettes/day

          -  obesity-body mass index &gt; 35

          -  history of clinical cardiovascular disease

          -  history of cerebrovascular disease

          -  history of thromboembolic disease

          -  coronary calcium score â‰¥ 50 units

          -  dyslipidemia-LDL cholesterol &gt;190 mg/dl

          -  hypertriglyceridemia-triglycerides &gt;400 mg/dl

          -  lipid lowering medication (statin, fibrate,or &gt; 500 mg/day of niacin)

          -  nut allergy (Prometrium includes peanut oil)

          -  uncontrolled hypertension-systolic BP &gt;150 and/or diastolic BP &gt; 95

          -  hysterectomy

          -  history of, or prevalent, chronic diseases including any cancer (other than basal cell
             skin cancers), renal failure, cirrhosis, diabetes mellitus, and endocrinopathies other
             than adequately treated thyroid disease

          -  known HIV infection and/or medications for HIV infection

          -  results of any safety laboratory test chemistries, (TSH, CBC, U/A) more than 20%
             abnormal
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>42 Years</minimum_age>
    <maximum_age>58 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S Mitchell Harman, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kronos Longevity Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederick Naftolin, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kronos Longevity Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Mendelsohn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Howard Hodis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew Budoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sanjay Asthana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dennis M Black, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kronos Longevity Research Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016-3452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University Medical Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington/VA Puget Sound, HCS</name>
      <address>
        <city>Seattle/Tacoma</city>
        <state>Washington</state>
        <zip>98493</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.keepstudy.org</url>
    <description>Information on hormone treatment and KEEPS rationale</description>
  </link>
  <link>
    <url>http://www.kronosinstitute.org</url>
    <description>Information on sponsoring institution</description>
  </link>
  <reference>
    <citation>Harman SM, Naftolin F, Brinton EA, Judelson DR. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence. Ann N Y Acad Sci. 2005 Jun;1052:43-56.</citation>
    <PMID>16024750</PMID>
  </reference>
  <reference>
    <citation>Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, Miller VM, Naftolin F, Santoro N. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric. 2005 Mar;8(1):3-12.</citation>
    <PMID>15804727</PMID>
  </reference>
  <reference>
    <citation>Harman SM, Brinton EA, Clarkson T, Heward CB, Hecht HS, Karas RH, Judelson DR, Naftolin F. Is the WHI relevant to HRT started in the perimenopause? Endocrine. 2004 Aug;24(3):195-202.</citation>
    <PMID>15542885</PMID>
  </reference>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>September 10, 2009</last_update_submitted>
  <last_update_submitted_qc>September 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2009</last_update_posted>
  <responsible_party>
    <name_title>S. Mitchell Harman, MD, PhD/Director</name_title>
    <organization>Kronos Longevity Research Institute</organization>
  </responsible_party>
  <keyword>Perimenopause</keyword>
  <keyword>Coronary Disease</keyword>
  <keyword>Estrogen Replacement Therapy</keyword>
  <keyword>Hormone Replacement Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

